Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

BACKGROUND: The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is the prolonged suppression of testosterone levels after the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Ohlmann, Carsten-Henning, Jäschke, Michelle, Jaehnig, Peter, Krege, Susane, Gschwend, Jürgen, Rexer, Heidrun, Stöckle, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628432/
https://ncbi.nlm.nih.gov/pubmed/28978327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-017-2195-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados